HDAC9
HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.
Overview
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Panobinostat, HDAC Inhibitor REC-2282, Vorinostat and Trichostatin A. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.34, clinical 0.95).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.
- 1 · What it is
HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.
- 2 · What goes wrong in cancer
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
- 3 · How drugs use it
No product in this corpus aims at HDAC9 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:14065 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UKV0 (protein name, function text, keywords and locations (REST API)); CIViC gene HDAC9 (3 evidence items, 0 assertions, 2 variants; diseases: Glioblastoma, Breast Cancer, Oesophageal Cancer (GraphQL API, CC0)); Open Targets ENSG00000048052 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: plasma cell myeloma 0.56, non-Hodgkin lymphoma 0.58, skin cancer 0.51, primary cutaneous T-cell non-Hodgkin lymphoma 0.51 (GraphQL API, CC0))
Biology
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription. Isoform 3 lacks active site residues and therefore is catalytically inactive. Represses MEF2-dependent transcription by recruiting HDAC1 and/or HDAC3. Seems to inhibit skeletal myogenesis and to be involved in heart development. Location: Nucleus (UniProt). Locus 7p21.1 (HGNC).
- Breast cancer: CIViC evidence names this disease
- Oesophageal cancer: CIViC evidence names this disease
- Non-Hodgkin lymphoma: Open Targets association 0.58 with non-Hodgkin lymphoma (MONDO_0018908)
- Multiple myeloma: Open Targets association 0.56 with plasma cell myeloma (MONDO_0009693)
- Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898)
- Glioma & glioblastoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.95; CIViC holds 3 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HDAC9" OR ABSTRACT:"HDAC9" OR TITLE:"histone deacetylase 9" OR ABSTRACT:"histone deacetylase 9" OR TITLE:"Histone deacetylase 9" OR ABSTRACT:"Histone deacetylase 9" OR TITLE:"KIAA0744" OR ABSTRACT:"KIAA0744" OR TITLE:"HD7" OR ABSTRACT:"HD7" OR TITLE:"HDAC7B" OR ABSTRACT:"HDAC7B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HDAC9, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetIL2RG
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TargetIL2RB
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TrialExtracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Non-Hodgkin lymphoma (all types).
- TechnologyElectron beam therapy systems (linac electrons, total skin electron units, mobile electron IORT)
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types), Breast cancer (all types).
- TechnologySuperficial and orthovoltage radiotherapy for skin cancer
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types).
- TechnologyFLASH research accelerators (Oriatron, Mobetron FLASH, ProBeam FLASH)
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types).
- TechnologyConfocal microscopy and optical coherence tomography for skin (VivaScope, VivoSight, deepLive)
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Skin cancer (all types).